Drug intelligence / Profile preview

ICTP-401

Development stage: Preclinical
Lead developer: InnoCure Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

ICTP-401 is a preclinical drug candidate developed by InnoCure Therapeutics for the treatment of pancreatic cancer. It utilizes the company's proprietary Targeted Protein Degradation (TPD) platform, specifically employing PROTAC (Proteolysis-Targeting Chimera) and MILPROTAC (Multi-specific Induced Proximity-based Targeted Protein Degradation) technologies. While the specific molecular target of ICTP-401 has not been publicly disclosed, the drug is designed to selectively degrade disease-causing proteins via the ubiquitin-proteasome system. As of early 2024, the candidate is in the discovery phase of development.

Beyond the preview

Go deeper on ICTP-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICTP-401.

Explore the full profile